drugset / Trial / NCT05047172
Comparison of Anti-coagulation and Anti-Platelet Therapies for Intracranial Vascular Atherostenosis
Phase 3
Active not recruiting
1683 enrolled
University of Florida
AstraZeneca · collabJanssen Scientific Affairs, LLC · collabMedical University of South Carolina · collabNational Institute of Neurological Disorders and Stroke (NINDS) · collabUniversity of Cincinnati · collab
RandomizedParallel-groupQuadruple-blindPrevention
Summary
The primary goal of the trial is to determine if the experimental arms (rivaroxaban or ticagrelor or both) are superior to the clopidogrel arm for lowering the 1-year rate of ischemic stroke, intracerebral hemorrhage, or vascular death.
Timeline
- Start
- 2022-08-02
- Primary completion
- 2027-01-31
- Completion
- 2027-01-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Clopidogrel | Small molecule | 75 mg | — |
| Subject | Rivaroxaban | Other / unclassified | 2.5 mg | — |
| Subject | Ticagrelor | Small molecule | 90 mg | — |
| Comparator | Aspirin | Small molecule | 81 mg | — |